Detalhe da pesquisa
1.
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis.
Future Oncol
; 17(32): 4415-4424, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34402681
2.
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
Mol Diagn Ther
; 28(1): 37-51, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37874465
3.
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
JCO Precis Oncol
; 7: e2300073, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37262392
4.
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report.
Front Oncol
; 13: 1310452, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38188286
5.
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.
J Thorac Oncol
; 18(5): 576-586, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36646211
6.
Principles of medical and oncological management of giant masses of the mediastinum: a narrative review.
Mediastinum
; 6: 35, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36582971
7.
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC.
Ther Adv Med Oncol
; 14: 17588359211058391, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173818
8.
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Eur J Cancer
; 150: 99-107, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33892411
9.
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Clin Lung Cancer
; 22(5): 423-431, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33849808
10.
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience.
Lung Cancer
; 149: 5-9, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32932213
11.
Pulmonary adenocarcinoma with psammoma bodies is associated with a specific endobronchial ultrasound pattern and a high prevalence of actionable driver mutations.
Lung Cancer
; 147: 204-208, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32736279
12.
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer.
Chin Clin Oncol
; 13(2): 30, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600809
13.
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.
Clin Cancer Res
; 26(2): 518-519, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31941684